The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis

There are a broad range of disease-modifying therapies (DMTs) available in relapsing-remitting multiple sclerosis (RRMS), but limited biomarkers exist to personalise DMT choice. All DMTs, including monoclonal antibodies such as rituximab and ocrelizumab, are effective in preventing relapses and pres...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurotherapeutics
Autors principals: Zhong, Michael, van der Walt, Anneke, Campagna, Maria Pia, Stankovich, Jim, Butzkueven, Helmut, Jokubaitis, Vilija
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Current Perspectives
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851267/
https://ncbi.nlm.nih.gov/pubmed/33058021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-020-00950-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars